Publication:
Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients

Simple item page
dc.contributor.authorÖZTÜRK, DİLEK
dc.contributor.authorYuksel, Merve Kurtan
dc.contributor.authorOztas, Ezgi
dc.contributor.authorOzhan, Gul
dc.contributor.authorTurker, Aylin Altanlar
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorOkyar, Alper
dc.contributor.authorKara, Zeliha Pala
dc.contributor.institutionauthorÖZTÜRK CİVELEK, DİLEK
dc.date.accessioned2019-10-05T13:18:17Z
dc.date.available2019-10-05T13:18:17Z
dc.date.issued2019-08-01
dc.description.abstractCapecitabine is an oral prodrug and converted to 5-fluorouracil using three-step enzymatic pathways which include carboxylesterase (CES). Interindividual differences in the activities of drug-metabolizing enzymes may affect efficacy and toxicity. The aim of this study is to evaluate the association of Single nucleotide polymorphisms (SNP) in CES1 with the pharmacokinetic and adverse effects of capecitabine. Plasma samples were obtained from 7 breast and colorectal cancer patients who were treated with capecitabine-based chemotherapy (1000-1250 mg/m(2)) at 0.5, 1, 2, 3 and 4 hours following drug administration on their first day of the first cycle. The plasma concentrations of the capecitabine were determined by using a high-pressure liquid chromatography-UV detector. SNP (rs8192950) was genotyped using the reverse transcription-polymerase chain reaction. Patients were found to have heterozygote (57%), wild (29%), and mutant (14%) distributions of genotypes (p=0.909). The mean plasma area under the curve (AUC(0-4h)) was 4.60 +/- 2.25 mu g.h/mL, and maximum plasma concentration (C-max) was 3.19 +/- 2.5 mu g/mL. There were no statistically significant differences between genotypes and AUC values (p=0.2236) and the most frequently observed side effects were diarrhea (p=0.1028), asthenia (p=0.6456), anemia (p=0.6456), emesis (p=0.3499). This is the first study evaluating an association of genetic variation in CES1 (rs8192950) with pharmacokinetic and adverse effects of capecitabine. Therefore, additional study in larger groups of patients is required to support our study.
dc.description.sponsorshipİstanbul Üniversitesi
dc.identifier10.2147/copd.s182731
dc.identifier.citationYuksel M. K. , ÖZTÜRK D., Oztas E., Ozhan G., Turker A. A. , Korkmaz T., Okyar A., Kara Z. P. , -Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients-, ISTANBUL JOURNAL OF PHARMACY, cilt.49, ss.64-69, 2019
dc.identifier.doi10.26650/istanbuljpharm.2019.19018
dc.identifier.trdizintrdizin
dc.identifier.urihttps://hdl.handle.net/20.500.12645/1874
dc.identifier.wosWOS:000484810700004
dc.language.isoen
dc.titleEvaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients
dc.typeArticle
dspace.entity.typePublication
local.article.journalnameInternational journal of chronic obstructive pulmonary disease
local.avesis.id2d39a20c-da63-4aba-b1d0-4c1b4cd01465
local.avesis.response1744
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication821c461c-752b-4a78-a2e5-a6aaf5076b88
relation.isAuthorOfPublication.latestForDiscovery821c461c-752b-4a78-a2e5-a6aaf5076b88
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Collections
Yayınlar - Eserler
Eczacılık Fakültesi
TR Dizin İndeksli Yayınlar Koleksiyonu